Only China locations: A Phase I Study to Evaluate the Safety, Pharmacokinetics and Efficacy of SY-5007 in Patients With Advanced Solid Tumors

Inclusion criteria:
Dose-escalation Part: patients must have confirmed advanced solid tumors with RET alteration (fusion or mutation) and have progressed after standard therapy, or no standard or available curative therapy exists.
Dose-expansion Part: Patients with advanced tumor must have confirmed RET alteration, and either have progressed after standard therapy or no standard/ available curative therapy exists.

Sponsor/Collaborator: Shouyao Holdings (Beijing) Co. LTD

Contact and Locations:
Study contact: Yinghui Sun, PhD
Phone Number: 86-10-88858616
Email: yhsun@centaurusbio.com
Locations: https://clinicaltrials.gov/study/NCT05278364#contacts-and-locations

Mechanism of action: Oral RET selective Inhibitor

Phases: Phase 1

NCT Number: NCT05278364

URL: https://clinicaltrials.gov/study/NCT05278364

Status: Recruiting